In: Neuroradiology, 2015, vol. 57, no. 10, p. 1045-1054
|
In: The International Journal of Cardiovascular Imaging, 2015, vol. 31, no. 5, p. 915-926
|
In: European Radiology, 2015, vol. 25, no. 7, p. 2067-2073
|
In: Value in Health, 2019, vol. 22, no. 12, p. 1355–1361
Elderly patients receive bare metal stents instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT). The SENIOR trial compared outcomes between these 2 types of stents combined with a short duration of DAPT. A significant decrease in the number of patients with at least 1 major adverse cardiac and cerebrovascular event (MACCE) was noted in the DES...
|
In: Catheterization and Cardiovascular Interventions, 2019, p. ccd.28376
To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second‐generation Resolute™ zotarolimus‐eluting stent (R‐ ZES) in patients enrolled in the DAPT‐STEMI Trial (NCT01459627).Background: R‐ ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is...
|
In: Cardiovascular Revascularization Medicine, 2019, vol. 20, no. 7, p. 577–582
Background: The advent of bioresorbable vascular scaffolds (BVS) was considered as a potential improvement in percutaneous coronary intervention (PCI) after the groundbreaking development of drug eluting stents (DES). However, the clinical performance, long-term safety and efficacy of BVS in complex coronary lesions remain uncertain. COMPARE ABSORB, a multicenter, single blind, prospective ...
|
In: Internal and Emergency Medicine, 2014, vol. 9, no. 3, p. 335-339
|
In: The International Journal of Cardiovascular Imaging, 2014, vol. 30, no. 1, p. 207-209
|
In: European Radiology, 2014, vol. 24, no. 11, p. 2810-2818
|
In: Herz, 2014, vol. 39, no. 6, p. 668-671
|